BridgeBio Pharma, Inc. — Director's Dealing 2020

Dec 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-12-21

Reporting Person: SCHELLER RICHARD H (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-21	Common Stock	S	14928	$64.8069	Disposed	91333	Direct
2020-12-21	Common Stock	S	45473	$65.4828	Disposed	45860	Direct

Footnotes

F1: Represents the weighted average sale price of the shares sold from $64.15 to $65.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 and 2.

F2: Represents the weighted average sale price of the shares sold from $65.15 to $65.76 per share.